Forward Citations = 0

Loading Chart...

8 inventors (with patents filed for the assignee):

Zhenfan Yang (3 out of 16 patents)

Xiaolin Zhang (3 out of 24 patents)

Honchung Tsui (2 out of 12 patents)

4. Changhe Qi (2 out of 12 patents)

5. Qingbei Zeng (2 out of 12 patents)

6. Mei Wang (1 out of 6 patents)

7. Yu Bai (1 out of 2 patents)

8. Qiuli Guo (1 out of 1 patent)

3 patents: Sort by Forward Citations

1. 12723091 - NOVEL ANTI-FGFR2B ANTIBODIES (2026-09-01),

2. 12630565 - DNA-dependent protein kinase inhibitor (2026-05-19),

3. 12606544 - JAK1 selective kinase inhibitor (2026-04-21),

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

3 Patents

#657 in Shanghai

#8,360 in China

Shanghai, China

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Forward Citations = 0

8 inventors:

Zhenfan Yang (3 out of 16 patents)

Xiaolin Zhang (3 out of 24 patents)

Honchung Tsui (2 out of 12 patents)

4. Changhe Qi (2 out of 12 patents)

5. Qingbei Zeng (2 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Dizal (Jiangsu) Pharmaceutical Co., Ltd.. Retrieved from https://idiyas.com/company/dizal-jiangsu-pharmaceutical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]